1. 2201 Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948). (September 2015) Authors: Cunningham, D.; Smyth, E.; Stenning, S.; Stevenson, L.; Robb, C.; Allum, W.; Grabsch, H.; Alderson, D.; Riddell, A.; Chua, S.; Crosby, T.; Mason, R.; Griffin, M.; Mansoor, W.; Coxon, F.; Falk, S.; Rowley, S.; Sumpter, K.; Blazeby, J.; Langley, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. (December 2016) Authors: Graham, J.; Boyd, K.; Coxon, F.; Wall, L.; Eatock, M.; Maughan, T.; Highley, M.; Soulis, E.; Harden, S.; Bützberger-Zimmerli, P.; Evans, T. Journal: BMC research notes Issue: Volume 9:Number 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗